Aurobindo Pharma has disclosed, pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, that the Hon'ble High Court of Telangana, Hyderabad, passed an order dated May 6, 2026, dismissing a writ petition filed by certain members of its promoter and promoter group. The order was received by the company on May 15, 2026, and the intimation was filed on May 16, 2026.

Background of the Settlement Proceedings

The matter traces its origins to a settlement application filed by the petitioners with SEBI under the SEBI (Settlement) Regulations, 2018, in relation to alleged violations of Regulations 3 and 4 read with Regulation 12(2) of the SEBI (Prohibition of Insider Trading) Regulations, 1992. SEBI passed a settlement order on May 6, 2020, in response to this application.

Subsequently, on October 23, 2020, SEBI issued a communication directing the petitioners to deposit profits made from trading in the shares of the company, along with applicable interest, into the Investor Protection and Education Fund (IPEF) within 15 calendar days. The petitioners challenged this communication by filing a writ petition before the Hon'ble High Court of Telangana, Hyderabad.

Key Details of the Court Order

The following table summarises the key particulars of the regulatory order as disclosed by the company:

Petitioners and Their Relationship to the Company

The individuals and entity named in the proceedings are members of the promoter and promoter group of Aurobindo Pharma:

• Mr. P. V. Ramprasad Reddy — Promoter of the company
• Ms. P. Suneela Rani — Member of the promoter group
• Mr. Kambam Prasad Reddy — Member of the promoter group
• Trident Chemphar Limited — Member of the promoter group

Company's Stated Position and Next Steps

Aurobindo Pharma has clarified that since the order is directed against the petitioners in their individual or associated capacities, it has no impact on the company's financials, operations, or other activities. The petitioners, in consultation with their respective legal advisors, are stated to be evaluating the future course of action following the dismissal of the writ petition. The company's disclosure was digitally signed by B. Adi Reddy, Company Secretary, on May 16, 2026.

Aurobindo Pharma 's subsidiary, CuraTeQ Biologics, has secured a key regulatory milestone with the receipt of marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO). The approval, granted in the form of Form CT 23, covers Bevqolva®, the company's biosimilar version of bevacizumab.

Regulatory Approval Details

The CDSCO marketing authorisation represents a critical step for CuraTeQ Biologics in bringing Bevqolva® to the Indian market. Bevacizumab is a widely recognised biologic used in oncology, and the biosimilar approval positions CuraTeQ Biologics to participate in this therapeutic segment domestically.

Strategic Significance

The approval of Bevqolva® under Form CT 23 highlights Aurobindo Pharma's strategic focus on expanding its biologics and biosimilars portfolio through CuraTeQ Biologics. This development reflects the company's efforts to strengthen its presence in the high-growth biologics segment within the Indian pharmaceutical landscape.